<DOC>
	<DOCNO>NCT01527838</DOCNO>
	<brief_summary>This trial prospective , open-label , single-arm trial safety single FT1050-treated CB unit hematopoietic reconstitution reduced-intensity condition regimen hematologic malignancy . A maximum 40 eligible adult subject enrol treated trial approximately 2-4 center within U.S .</brief_summary>
	<brief_title>Single Treatment With FT1050 Ex-vivo Modulated Umbilical Cord Blood Unit</brief_title>
	<detailed_description>The trial conduct three sequential cohort 6-12 evaluable subject . Cohort 1 enroll eligible subject single CB unit identify meet minimum HLA-matching criterion minimum pre-cryopreservation total nucleate cell ( TNC ) dose least 2.5 x 10^7 cells/kg . Cohort 2 identical Cohort 1 , except TNC dose CB unit must 2.0 - &lt; 2.5 x 10^7 cells/kg . Finally , Cohort 3 identical Cohort 2 , except TNC dose CB unit must 1.5 - &lt; 2.0 x 10^7 cells/kg . If safety rule trigger , study proceed next dosing cohort . Within dose cohort , three subject may Day 42 one time , unless already engraft neutrophil . The final dosing cohort define last cohort 12 evaluable subject treat stop rule trigger . The corresponding TNC dose level consider minimally acceptable TNC dose level .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>1 . Subjects hematologic malignancy allogeneic stem cell transplantation deem clinically appropriate . Eligible disease stage include : NonHodgkin 's lymphoma Hodgkin 's lymphoma Chronic lymphocytic leukemia ( CLL ) Acute myelogenous leukemia ( AML ) Chronic myelogenous leukemia ( CML ) 2 . Lack 56/6 HLAmatched relate 8/8 HLAA , B , C , DRß1 match unrelated donor ; unrelated donor available within appropriate timeframe . Identification suitable backup CB unit ( ) ( single unit precryopreservation cell dose ≥ 2.5 x 10^7 TNC/kg two unit precryopreservation cell dose ≥ 1.5 x 10^7 TNC/kg ) meeting minimum HLA match criterion . An acceptable alternative one two backup CB unit ( ) identification eligible related haploidentical donor meet minimum HLA match criterion . 3 . Age 1865 year . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 5 . Signed IRB approve Informed Consent Form ( ICF ) . 1 . The following hematologic malignancy exclude : Myelofibrosis ( Agnogenic Myeloid Metaplasia ) Aplastic anemia . 2 . Previous treatment include allogeneic transplant 3 . Cardiac disease : symptomatic congestive heart failure evidence leave ventricular 4. dysfunction ( Ejection fraction &lt; 40 % ) measure gated radionucleotide ventriculogram echocardiogram ; active angina pectoris , uncontrolled hypertension ; history myocardial infarction depress ejection fraction . 5 . Pulmonary disease : symptomatic chronic obstructive lung disease , symptomatic restrictive lung disease , correct DLCO &lt; 50 % predict , correct hemoglobin . 6 . Renal disease : serum creatinine &gt; 2.0 mg/dl calculate creatinine clearance &lt; 40 mL/min 7 . Hepatic disease : serum bilirubin &gt; 2.0 mg/dl ( except case Gilbert 's syndrome ongoing hemolytic anemia ) , SGOT SGPT &gt; 3 x upper limit normal . 8 . Neurologic disease : symptomatic leukoencephalopathy , active CNS malignancy neuropsychiatric abnormality believe preclude transplantation . 9 . HIV antibody . 10 . Uncontrolled infection . 11 . Pregnancy breast feed mother . 12 . Inability comply requirement care allogeneic stem cell transplantation . 13 . Participation concurrent clinical trial novel , unapproved investigational agent &lt; 30 day prior Day 0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Hematologic malignancy</keyword>
</DOC>